Congenital Heart Disease clinical trials

Explore recruiting congenital heart disease clinical trials.

Recruiting congenital heart disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Congenital Heart Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Theophylline Effects in the Fontan Circulation

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A prospective, open-label, non-randomized, multicentre trial to assess the safety and PD of Cangrelor as procedural platelet inhibitor in paediatric subjects from birth to <18 years of age undergoing diagnostic and/or therapeutic percutaneous vascular procedures for management of congenital heart disease

Netherlands, Germany, Portugal, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

CeRebrUm and CardIac protection with ALlopurinol in Neonates with Critical Congenital Heart Disease requiring Cardiac Surgery with Cardiopulmonary Bypass

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Pilot Study on the Use of Gadopiclenol for Enhanced Cardiac MRI in Children with Congenital Heart Conditions: A self-controlled, non-randomised, open-label study to compare the image quality and diagnostic performance of gadopiclenol versus gadoterate meglumine

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension

Greece, Belgium, Italy, Poland, France, Sweden +1 more

Phase II and Phase III (Integrated) EU CTIS Study details

Congenital Heart Disease trials by city

Congenital Heart Disease in Toronto Congenital Heart Disease in Vancouver Congenital Heart Disease in Montreal Congenital Heart Disease in Calgary Congenital Heart Disease in Edmonton Congenital Heart Disease in Ottawa Congenital Heart Disease in Winnipeg Congenital Heart Disease in Quebec City Congenital Heart Disease in Hamilton Congenital Heart Disease in Kitchener Congenital Heart Disease in London Congenital Heart Disease in Halifax Congenital Heart Disease in New York Congenital Heart Disease in Los Angeles Congenital Heart Disease in Chicago Congenital Heart Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease